Lundbeck's insomnia treatment gaboxadol enhances slow-wave sleep, data shows

By Elaine Rigoli

Tampa, Fla., May 25 - H. Lundbeck A/S announced results of two phase 2 clinical trials with gaboxadol, an investigational agent for the treatment of insomnia.

In the primary insomnia polysomongraph (PSG) study, short-term treatment with gaboxadol improved sleep maintenance, enhanced slow-wave sleep and was generally well-tolerated with no next-day residual effects, according to a news release.

In the transient insomnia study, gaboxadol 10 and 15 mg effectively improved traditional PSG and self-reported sleep maintenance and induction measures, the release said.

"The phase 2 data presented demonstrates a clear differentiation of gaboxadol by enhancing the slow-wave activity. We believe that enhanced slow-wave sleep will open another field of research to add benefit for patients' condition and performance," Lundbeck head of development Anders Gersel Pedersen said in the release.

Gaboxadol is in clinical phase 3, which comprises about 5,000 patients. Together with partner Merck, the companies expect to file gaboxadol for approval in the United States in the beginning of 2007.

Based in Copenhagen, Denmark, Lundbeck is an international pharmaceutical company engaged in the research and development of drugs for the treatment of psychiatric and neurological disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.